X4 Pharmaceuticals, Inc. develops and commercializes therapies for rare hematology diseases, centered on mavorixafor, an oral CXCR4 antagonist marketed in the U.S. as XOLREMDI® in its first indication. Company news covers regulatory and commercial updates for XOLREMDI, including European authorization for WHIM syndrome and the Norgine license and supply relationship for selected ex-U.S. territories.
Recurring updates also address the 4WARD Phase 3 program evaluating mavorixafor in chronic neutropenia, quarterly financial results, product revenue, research and development spending, cash resources, restructuring effects, conference participation, and equity inducement grants under Nasdaq listing rules.
X4 Pharmaceuticals (XFOR) will participate in a fireside chat at the 2026 Wells Fargo Healthcare Conference on September 10, 2026, at 9:30 a.m. ET.
A live and archived webcast will be available via the Investors > Events and Presentations section of the company’s website. X4 develops therapies for rare hematology diseases and has commercialized mavorixafor (XOLREMDI) in the U.S., with a global pivotal Phase 3 4WARD trial in chronic neutropenic disorders and FDA Fast Track designation for chronic neutropenia.
X4 Pharmaceuticals (XFOR) reports a positive outcome from an FDA Type C Meeting on its global 4WARD Phase 3 chronic neutropenia trial. The FDA agreed that reducing the trial sample size from 176 to 126 participants maintains adequate statistical power for the co-primary endpoints of annualized infection rate reduction and positive absolute neutrophil count (ANC) response. The agency also indicated that the proposed safety database would be acceptable to support a potential supplemental new drug application (sNDA) for mavorixafor in chronic neutropenia.
X4 expects to complete enrollment in 4WARD by year-end 2026 and to report topline data in the first half of 2028. The 52-week, randomized, double-blind, placebo-controlled, multicenter trial will enroll 126 patients aged 12 and older with chronic neutropenia and recurrent and/or serious infections. Mavorixafor, an oral CXCR4 antagonist already marketed in the U.S. as XOLREMDI in another indication, has Fast Track designation from the FDA for treating chronic neutropenia.
X4 Pharmaceuticals (Nasdaq: XFOR) granted inducement equity awards to new employees effective August 31, 2026 under its 2019 Inducement Equity Incentive Plan. According to X4 Pharmaceuticals, the awards are stock options to purchase an aggregate of 50,000 common shares at an exercise price of $4.04, equal to the closing price on the grant date, with a ten-year term.
Each option vests over four years: 25% after 12 months and the remainder monthly over the next 36 months, subject to continued employment. The grants were approved by the board’s Compensation Committee in line with Nasdaq Listing Rule 5635(c)(4). X4 is also advancing mavorixafor (XOLREMDI) for rare hematology diseases, including a global Phase 3 4WARD trial in chronic neutropenic disorders.
X4 Pharmaceuticals (Nasdaq:XFOR) reported financial results for the quarter ended June 30, 2026 and detailed progress across its rare hematology portfolio. Revenue was $8.8 million for the quarter and $11.5 million for the first half of 2026, including $2.4 million and $4.8 million in net U.S. XOLREMDI® product sales and $6.4 million and $6.7 million in license and other revenue, largely from its Norgine agreement.
Research and development expenses declined to $15.1 million in the quarter, while general and administrative expenses fell to $8.5 million. Net loss narrowed to $16.2 million, or $(0.13) per share, for the quarter. Cash, cash equivalents, and marketable securities totaled approximately $208 million at June 30, 2026, which the company said provides a cash runway into 2029. Operationally, X4 transitioned management of its global Phase 3 4WARD chronic neutropenia trial to a premier CRO, continued enrolling patients at over 110 sites, and expects an FDA meeting update and enrollment completion timing by the end of the third quarter of 2026. The European Commission granted marketing authorization for XOLREMDI for WHIM syndrome, with commercialization in Europe led by partner Norgine and up to an additional €221 million in potential milestones plus escalating double-digit royalties.
X4 Pharmaceuticals (Nasdaq: XFOR) issued inducement equity awards to new employees effective July 31, 2026 under its 2019 Inducement Equity Incentive Plan. The awards comprise stock options to purchase an aggregate of 12,000 shares of common stock, granted pursuant to Nasdaq Listing Rule 5635(c)(4) and approved by the Compensation Committee.
The options have a ten-year term and an exercise price of $3.98 per share, equal to X4’s closing stock price on July 31, 2026. Each option vests over four years, with 25% vesting after 12 months and the remainder vesting monthly over 36 months, subject to continued employment and the terms of the 2019 Inducement Plan and related award agreements. X4 focuses on rare hematology diseases and has developed mavorixafor, approved as XOLREMDI for WHIM syndrome, and is running the global Phase 3 4WARD trial in chronic neutropenic disorders.
X4 Pharmaceuticals (Nasdaq:XFOR) granted stock options as inducement awards to new employees under its 2019 Inducement Equity Incentive Plan, effective July 6, 2026.
The awards cover 750,000 shares at a $4.03 exercise price, with a ten-year term and four-year vesting schedule.
X4 Pharmaceuticals (Nasdaq:XFOR) appointed Kelly Gold to its Board of Directors effective July 1, 2026. She will serve as an independent director and member of the Audit Committee. Her background spans public company CFO experience, capital markets, biotech finance, and engineering and biochemistry training.
According to X4 Pharmaceuticals, the company aims to leverage her expertise as it advances mavorixafor toward potential approval and commercialization in rare hematology and rare disease settings.
X4 Pharmaceuticals (Nasdaq:XFOR) granted inducement stock options to new employees under its 2019 Inducement Equity Incentive Plan, effective May 29, 2026. The awards cover 160,000 shares at an exercise price of $4.31 per share, with a ten-year term and four-year vesting schedule.
X4 Pharmaceuticals (Nasdaq:XFOR) announced that management will present at the 2026 Jefferies Global Healthcare Conference on Thursday, June 4, 2026, at 3:45 p.m. ET. A live and archived webcast of the presentation will be available via the Investors section of the company’s website.
X4 Pharmaceuticals (Nasdaq: XFOR) reported Q1 2026 results and a corporate update on May 6, 2026. Key items: EU marketing authorization for XOLREMDI (mavorixafor) for WHIM syndrome, continued enrollment progress in the global 4WARD Phase 3 chronic neutropenia trial, and a $233.7M cash balance providing runway through 2028. The Norgine license could yield up to €226M in milestones plus escalating royalties; Q1 revenue was $2.7M versus $28.8M prior year, and net loss was $(20.2)M.